Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Natalia Maximovsky

Nurse Practitioner, Adult Health Staten Island, NY Nurse Practitioner

NPI 1265990097 CMS profile 10613418

11 Ralph Pl, Staten Island, NY 10304

Open in the dashboard

General payments

$1,900

104 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Natalia Maximovsky of Staten Island, NY is reported in the CMS Open Payments database as having received $1,900 across 104 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $262 12
2024 General $564 29
2023 General $410 21
2022 General $271 16
2021 General $392 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Natalia Maximovsky
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Natalia Maximovsky were reported at $262. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Natalia Maximovsky Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $392 $138 $43–$438 $132
2022 $271 $165 $54–$494 $149
2023 $410 $178 $61–$549 $160
2024 $564 $186 $62–$575 $164
2025 $262 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $491 31 payments
  2. Aucta Pharmaceuticals, Inc. $285 16 payments
  3. Scilex Pharmaceuticals Inc. $214 9 payments
  4. Otsuka America Pharmaceutical, Inc. $212 9 payments
  5. Pfizer Inc. $139 8 payments
  6. Novartis Pharmaceuticals Corporation $85 5 payments
  7. Nestle HealthCare Nutrition Inc. $78 4 payments
  8. Exact Sciences Corporation $62 3 payments
  9. Avanir Pharmaceuticals, Inc. $37 2 payments
  10. Idorsia Pharmaceuticals US Inc $32 2 payments
  11. Other $265 15 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,900 104 payments
Products named General payments · program years 2021–2025
  1. Motpoly XR $285 16 payments
  2. CREON $237 18 payments
  3. LINZESS $229 16 payments
  4. ZTLido $214 9 payments
  5. REXULTI $212 9 payments
  6. UBRELVY $188 9 payments
  7. NURTEC ODT $106 6 payments
  8. ZENPEP $99 5 payments
  9. ELIQUIS $91 5 payments
  10. QULIPTA $51 3 payments
  11. Other $620 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 290 drugs

Part D claims

33,611

Median for Nurse Practitioner: 389

Drug cost

$4,128,824

Median for Nurse Practitioner: $21,885

Branded share of claims

30%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 916 $632,964
Linzess Linaclotide Brand 657 $368,764
Zenpep Lipase/Protease/Amylase Brand 264 $305,782
Diclofenac Sodium Generic 1,090 $303,558
Creon Lipase/Protease/Amylase Brand 222 $249,271
Januvia Sitagliptin Phosphate Brand 232 $156,273
Ozempic Semaglutide Brand 150 $136,659
Vascepa Icosapent Ethyl Brand 343 $127,760
Xarelto Rivaroxaban Brand 142 $104,072
Procrit Epoetin Alfa Brand 34 $86,573

The 10 drugs with the highest cost, of 290 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$594,891

Of which drugs: $3,743

Medicare patients

938

Average age 85

Services billed

11,172

676 women, 262 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Heart failure 75%
Arthritis 75%
Ischemic heart disease 73%
Alzheimer's or dementia 60%
Depression 49%
Atrial fibrillation 38%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent, 0.5 ml dosage 90658 Office 145 145 $3,106
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 212 648 $617

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Motpoly XR
  • Aucta Pharmaceuticals, Inc. $285
$285 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $79
$79 52 —
UBRELVY
  • AbbVie, Inc. $29
$29 18 —
ZTLido
  • Scilex Pharmaceuticals Inc. $23
$23 18 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

104 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record